Clinical Efficacy of Classical Ayurvedic Formulations Vatari Guggulu, Rasnasaptaka Kashaya, and Brihat Saindhavadya Taila in the Management of Rheumatoid Arthritis (Amavata): An Open-label Prospective Randomized Multicenter Study

JOURNAL TITLE: Journal of Research in Ayurvedic Sciences

1. Bharti
2. Avinash K Jain
3. Vinod B Kumavat
4. Maheswar Thugutla
5. Shashi Ghosh
6. Varanasi Subhose
7. Rakesh K Rana
Publishing Year
Author Affiliations
    1. Central Council for Research in Ayurvedic Sciences New Delhi, India
    1. Central Ayurveda Research Institute for Cardiovascular Diseases, New Delhi, India
    1. Regional Ayurveda Research Institute, Ranikhet, Uttarakhand India
    1. M.S. Regional Ayurveda Research Institute for Endocrine Disorders, Jaipur, Rajasthan, India
  • Article keywords
    Amavata, Ayurveda, Ayurvedic formulations, Efficacy, Rheumatoid arthritis, Safety.


    Introduction: Rheumatoid arthritis (RA) is an autoimmune disease resulting in chronic inflammation of the joints and extra-articular tissues characterized by persistent inflammatory synovitis, usually involving the peripheral joints in a symmetric manner. The disease Amavata described in Ayurveda has similar symptomatology to that of RA. Aims and objectives: To a ssess t he c linical e fficacy a nd safety of Vatari Guggulu, Rasnasaptaka kashaya, and Brihat Saindhavadya taila in patients suffering from RA. Materials and methods: A prospective, open-label multicenter study was carried out at four peripheral centers of the Central Council for Research in Ayurvedic Sciences (CCRAS). A total of 230 patients of RA satisfying the selection criteria were enrolled from the outpatient department (OPD) of these centers and were administered Vatari Guggulu 1.5 gm (3 tablets of 500 mg each) twice daily after food with lukewarm water, and Rasnasaptaka kashaya 15 ml with 1 gm Shunthi churna twice daily internally before food in group I and in group II along with these two drugs, Brihat Saindhavadya taila 20 ml was used twice daily for external application over affected joints. The duration of the treatment was 12 weeks. Paired sample t-test was used to compare mean change in the subjective and objective parameters, Disease Activity Score (DAS-28), disability index (the Indian Health Assessment Questionnaire), change in acute phase reactants—erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and Health Questionnaire short form (SF)-36 score from baseline to the 84th day. A p-value <0.05 was considered significant. Results: At the end of treatment (after a period of 84 days), statistically significant change (p-value <0.001) was observed in DAS-28 score, Disability index (the Indian Health Assessment Questionnaire), and Health Questionnaire SF-36 score in both the groups. Slight change in acute phase reactants—ESR, CRP—was also observed as compared with baseline; however, it was statistically insignificant. Conclusion: Vatari Guggulu, Rasnasaptaka kashaya (with Shunthi churna prakshepa), and Brihat Saindhavadya taila given in the above-mentioned dose were found effective and safe in patients suffering from RA.

    © 2019 Jaypee Brothers Medical Publishers (P) LTD.   |   All Rights Reserved